Testing two new drugs against cabozantinib for returning kidney cancer
Tests belzutifan with zanzalintinib in adults with kidney cancer that has returned.
Key facts
- Who runs it
- Merck Sharp & Dohme LLC
- Where
- Arezzo, Bari, Bologna, Florence, Genoa, Milan, Naples, Orbassano, Padova, Parma, Peschiera del Garda, Rome, and Rozzano, ItalySee the 14 sitesAlso in 23 other countries, 120 sites
- Trial code
- NCT07227402
- EU 2024-517136-21-00
- U1111-1311-6892
- Registry title
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 904 people, planned
- Started
- 26 Nov 2025
- Expected to end
- 21 Mar 2033
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Belzutifan
- Zanzalintinib
- Cabozantinib
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose advanced kidney cancer (clear cell type) came back during or after earlier treatment given after surgery with an anti-PD-1/L1 medicine.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced kidney cancer (renal cell cancer) that cannot be removed by surgery, Stage IV, with a clear cell part, with or without sarcomatoid features. The disease must be measurable (RECIST 1.1).
- Earlier treatment
- The cancer came back during adjuvant anti-PD-1/L1 therapy, or 24 months or less after the last dose. No other earlier drug treatment for the kidney cancer is allowed.
Main reasons for not taking part
- Serious heart or blood vessel disease within 12 months before the first dose
- Need for hemodialysis or peritoneal dialysis
- History of HIV infection, or hepatitis B or C
- Current pneumonitis or interstitial lung disease
- Major surgery within 8 weeks before randomization
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- The main inclusion criteria include but are not limited to the following:
- Has a histologically confirmed diagnosis of unresectable, advanced renal cell cancer (RCC) with clear cell component (with or without sarcomatoid features) i.e., Stage IV renal cell cancer per American Joint Committee on Cancer (AJCC) (8th Edition)
- Has measurable disease per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
- Has disease recurrence during adjuvant anti-programmed cell death 1/programmed cell death ligand 1 (PD-1/L1) therapy or recurrence ≤24 months following the last dose of adjuvant anti-PD-1/L1 therapy
- Has received no other prior systemic therapy for their RCC except for their adjuvant anti-PD-1/L1 therapy
Who cannot take part
- Had deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization
- Has had major surgery within 8 weeks before randomization or has not adequately recovered from major surgery or has ongoing surgical complications
- Has symptomatic pleural effusion (for example cough, dyspnea, pleuritic chest pain), ascites, or pericardial fluid requiring drainage within 4 weeks prior to randomization
- Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, new-onset angina, pulmonary embolism, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
- Has current pneumonitis/interstitial lung disease
- Has a gastrointestinal disorder including those associated with a high risk of perforation or fistula formation
- Has a serious active nonhealing wound/ulcer/bone fracture
- Has history of human immunodeficiency virus infection
- Has hepatitis B or hepatitis C virus
- Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram
- The main exclusion criteria include but are not limited to the following:
- Has a requirement for hemodialysis or peritoneal dialysis
- Has pharmacologically uncompensated, symptomatic hypothyroidism
This trial is currently available in Italy.
Also in 23 other countries, 120 sites
- Azienda Unita' Sanitaria Locale Toscana Sud EstArezzo, ItalyTaking people
- Azienda Universitaria Ospedaliera Consorziale Policlinico BariBari, ItalyTaking people
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, ItalyTaking people
- Azienda Ospedaliero-Universitaria CareggiFlorence, ItalyTaking people
- IRCCS Ospedale Policlinico San MartinoGenoa, ItalyTaking people
- Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyTaking people
- Azienda Ospedaliera di Rilievo Nazionale Antonio CardarelliNaples, ItalyTaking people
- Azienda Ospedaliero-Universitaria San Luigi GonzagaOrbassano, ItalyTaking people
- Istituto Oncologico VenetoPadova, ItalyTaking people
- Azienda Ospedaliero Universitaria ParmaParma, ItalyTaking people
- Ospedale P. Pederzoli Casa di Cura Privata S.p.A.Peschiera del Garda, ItalyTaking people
- Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyTaking people
- I.F.O. Istituti Fisioterapici OspitalieriRome, ItalyTaking people
- Humanitas Mirasole S.p.A.Rozzano, ItalyTaking people
About the trial
What the trial wants to find out
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib.
Read full original descriptionShow less
The goal of this study is to learn if:
People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.
The 2 groups in the trial
- Belzutifan plus ZanzalintinibTreatment being tested
Participants will receive belzutifan orally once daily (QD) PLUS zanzalintinib orally QD until one of the reasons for discontinuation of study intervention are met.
Treatment: Belzutifan and Zanzalintinib
- CabozantinibExisting treatment, for comparison
Participants will receive cabozantinib orally QD until one of the reasons for discontinuation of study intervention are met.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
- Plain-language title
- Testing two new drugs against cabozantinib for returning kidney cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 November 2026